Medifast Stock Forecast, Price & News

Medifast's stock was trading at $70.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MED stock has increased by 196.1% and is now trading at $208.57.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Medifast stock.
View analyst ratings for Medifast or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Medifast a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medifast wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Medifast is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Medifast.

Medifast, Inc. (NYSE:MED) posted its quarterly earnings results on Monday, November, 2nd. The specialty retailer reported $2.91 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.49 by $0.42. The specialty retailer had revenue of $271.40 million for the quarter, compared to analyst estimates of $242.50 million. Medifast had a net margin of 11.27% and a return on equity of 80.07%. The business's revenue was up 42.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.32 earnings per share.
View Medifast's earnings history.

Medifast declared a quarterly dividend on Thursday, December 10th. Stockholders of record on Tuesday, December 22nd will be given a dividend of $1.13 per share on Friday, February 5th. This represents a $4.52 annualized dividend and a dividend yield of 2.17%. The ex-dividend date is Monday, December 21st.
View Medifast's dividend history.

Medifast pays an annual dividend of $4.52 per share and currently has a dividend yield of 2.12%. Medifast does not yet have a strock track record of dividend growth. The dividend payout ratio of Medifast is 75.84%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Medifast will have a dividend payout ratio of 43.38% next year. This indicates that Medifast will be able to sustain or increase its dividend.
View Medifast's dividend history.

3 analysts have issued 12 month target prices for Medifast's shares. Their forecasts range from $210.00 to $250.00. On average, they anticipate Medifast's stock price to reach $233.00 in the next year. This suggests a possible upside of 11.7% from the stock's current price.
View analysts' price targets for Medifast or view Wall Street analyst' top-rated stocks.

Some companies that are related to Medifast include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Inter Parfums (IPAR), Prestige Consumer Healthcare (PBH), USANA Health Sciences (USNA), Veru (VERU), Revlon (REV) and Nature's Sunshine Products (NATR).
View all of MED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), The Home Depot (HD), The Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a number of retail and institutional investors. Top institutional investors include Chickasaw Capital Management LLC (0.26%), State of Alaska Department of Revenue (0.08%), Prairiewood Capital LLC (0.04%), Crossmark Global Holdings Inc. (0.04%), First Midwest Bank Trust Division (0.02%) and First Citizens Bank & Trust Co. (0.01%). Company insiders that own Medifast stock include Carl E Sassano, Jeffrey J Brown, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Chickasaw Capital Management LLC, First Midwest Bank Trust Division, and First Citizens Bank & Trust Co.. Company insiders that have sold Medifast company stock in the last year include Michael C Macdonald, and Scott Schlackman.
View insider buying and selling activity for Medifast or view top insider-selling stocks.

MED stock was purchased by a variety of institutional investors in the last quarter, including Prairiewood Capital LLC, Crossmark Global Holdings Inc., and Carroll Financial Associates Inc..
View insider buying and selling activity for Medifast or or view top insider-buying stocks.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MED stock can currently be purchased for approximately $208.57.

Medifast has a market capitalization of $2.45 billion and generates $713.67 million in revenue each year. The specialty retailer earns $77.92 million in net income (profit) each year or $5.96 on an earnings per share basis. Medifast employs 550 workers across the globe.

The official website for Medifast is www.medifast1.com.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]